Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Mirum Pharmaceuticals reported Q1 2026 net product sales of $159.9 million, up 43% from the prior year, driven by 55% growth in LIVMARLI sales. The company raised its full-year 2026 revenue guidance to $660 million to $680 million and ended the quarter with $420.6 million in unrestricted cash.
Key figures
- Revenue
- 159900000
- Guidance
- 2026 net product sales guidance increased to $660 to $680 million
- Iprd expense
- $726.3 million
- Livmarli sales
- $113.8 million
- Upfront payment
- $16 million
- Unrestricted cash
- $420.6 million
- Bile acid medicines sales
- $46.1 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.